Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition • 09-14 May 2026

Digital Poster

Cancer Detection and Therapies

Back to the Program-at-a-Glance

Cancer Detection and Therapies
Digital Poster
Preclinical
Monday, 11 May 2026
Digital Posters Row H
09:15 - 10:10
Session Number: 367-02
No CME/CE Credit
Similar Sessions
Tools for detecting or monitoring cancer micro-environment and therapeutics
  Figure 367-02-001.  Band-selective IR PRESS for brain tumor spectroscopy allows robust detection of lactate
Shun Kishimoto, Daniel Crooks, Peng Lu, Yuki Shibata, Olga Kim, Jeeva Munasinghe, Otowa Yasunori, Yamashita Kota, Kazutoshi Yamamoto, Jing Wu, Murali Krishna, jeff brender
Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States of America
Impact: Lactate is a key biomarker for tumor aggressiveness, but its clinical use is limited by lipid signal contamination. Our approach overcomes this challenge, providing a comprehensive metabolic profile that could improve diagnosis and therapy monitoring where conventional methods fail
  Figure 367-02-002.  Metal-free MRI probes based on peptide self-assembly for pancreatic cancer diagnosis
Xin Zhao, Hongyu Guo, Wentao Liu, Qian Zeng, Lei Wang, Yunan Zhao, Yaobang Shen, Yang Chen
Shenyang University of Technology, Shen Yang, China
Impact: This study develops a targeted metal-free MRI contrast agent with a prolonged imaging window. It overcomes limitations for patients with renal insufficiency or thalassemia and enhances diagnostic capabilities, advancing novel non-metallic imaging probes.
  Figure 367-02-003.  Tumor microenvironment: Insights from multiparametric MRI in mouse models of pancreatic ductal adenocarcinoma
Ramesh Paudyal, James Russell, H. Carl Lekaye, Joseph Deasy, John Humm, Muhammad Awais, Saad Nadeem, Amita Shukla-Dave
Memorial Sloan Kettering Cancer Center, New York, United States of America
Impact: mpMRI-derived QIBs with H&E show promise for assessing PDAC therapeutic response.
  Figure 367-02-004.  Detecting Metabolic Heterogeneity in Tumor Bearing Rats by Utilizing Unsupervised CEST Z-Spectral Analysis
Abeer Mathur, Anshuman Swain, Blake Benyard, Narayan Datt Soni, Sunil Khokhar, Paul Jacobs, Dipak Roy, neil wilson, Dushyant Kumar, Mohammad Haris, Ravinder Reddy
University of Pennsylvania, Philadelphia, United States of America
Impact: This label-free, voxel-wise anomaly mapping approach complements structural and multi pool-fit metrics, providing enhanced guidance for tumor detection and characterization of tumor heterogeneity.
  Figure 367-02-005.  Breast Cancer Habitats using CEST pH Imaging, Quantitative Susceptibility Mapping and Photoacoustic Oxygenation Maps at 7T
William Dominguez-Viqueira, Veronica Estrella, Epifanio Ruiz, Alex Lundberg
H. Lee Moffitt Cancer Center, Tampa, United States of America
Impact: Photoacoustic data was successfully coregistered with MRI. Tumor oxygen saturation maps showed a strong correlation with volume, susceptibility and pH in breast tumors. The methodology used in this work will be applied in the near future to study treatment response.
  Figure 367-02-006.  Multiparametric 1H/23Na MRI for analysing the ionic microenvironment within preclinical breast tumour models.
Alina Lavinia Capatina, Isaac Watson, Oliver Mundell, Aneurin Kennerley, William Brackenbury
University of York, York, United Kingdom
Impact: Each year ~670,000 women die of breast cancer. Multiparametric 1H/23Na MR tracking of the tissue ionic microenvironment enables testing of pioneering treatments targeting specific ion-transporters. We evidenced a novel connection between hypoxia-induced metabolic reprograming and Na+ dynamics.
  Figure 367-02-007.  ADC and Native T1 Mapping Histogram Analyses Reveal Tumor Proliferation and Microenvironment in Neuroblastoma
Haoru Wang, Xiang Cheng, Qian Hu, Lisha Nie, Weiyi Zhu, Yingxue Tong, Xin Chen, Ling He, Huiru Zhu, Jie Huang, Jiaxin Su, Ceng Zeng, Jinhua Cai
Children's Hospital of Chongqing Medical University, Chongqing, China
Impact: This study highlights the potential of combining ADC and native T1 mapping as noninvasive imaging biomarkers to characterize neuroblastoma microenvironmental heterogeneity, guiding future translational research and improving risk stratification in pediatric oncology.
  Figure 367-02-008.  The role and pathological analysis of DWI combined with CEST-MRI in the glioma zoning of rats
Xiaoli Wang, Yuxue Luan, Zhen Shen, Haimo Zhang, Xiaozu Zhang, Miao Yu, Yu Han, Peng Wu, Xizhen Wang
Shandong Second Medical University, Weifang, China
Impact: Multimodal magnetic resonance imaging can display the core and surrounding areas of glioma tissues, providing a basis for preoperative assessment of patients. The alterations in the microenvironment of each region provide a basis for revealing the mechanism of glioma invasion.
  Figure 367-02-009.  Longitudinal CEST MRI for applications to pancreatic cancer establishment and growth
Victoria Laney, Zoheb Ahasan, Kejia Cai
University of Illinois Chicago, Chicago, United States of America
Impact: CEST MRI non-invasively distinguishes metabolic signatures of PDAC within adipose microenvironments, linking creatine and amide exchange to thermogenic function and cancer progression. These findings highlight new imaging biomarkers for early detection and metabolic characterization in pancreatic cancer.
  Figure 367-02-010.  Dynamic evaluation of low-molecular-weight heparin enhancing immunotherapy in colon cancer models by multiparametric MRI
Xinhui Chen, Jiayang Wu, Dong Zhang, Geni Ye, JiFeng Chen, Xiaocong Ma, wei cui, Liangping Luo, Changzheng Shi, Xi Xu
The First Affiliated Hospital of Jinan University, Guangzhou, China
Impact: This study demonstrates that multiparametric MRI enables dynamic evaluation of heparin, PD-1 monoclonal antibody, and combination therapy in colon cancer providing imaging support for personalized treatment planning.

  Figure 367-02-011.  pH-Responsive Mn@ACC Nanoparticles: Performance & Biosafety as T₁ MRI Contrast Agents for Tumor Imaging
xue xiaoge xue, Yuyou Qiu, Xiance Zhao, Jinyuan Weng
The Tenth People's Hospital of Shanghai, 上海, China
Impact: This study develops a pH-responsive manganese-doped amorphous calcium carbonate nanoparticle (Mn@ACC) that serves as an efficient and safe MRI contrast agent for tumor diagnosis, advancing the clinical application of nanomedicine.
  Figure 367-02-012.  Early Metabolic Imaging Biomarkers of Pirtobrutinib Response in Mantle Cell Lymphoma by Magnetic Resonance Spectroscopy
Pradeep Kumar Gupta, David Rushmore, Skyler Nova, Fernando Arias-Mendoza, David Nelson, Mariusz Wasik, Kavindra Nath
University of Pennsylvania, Philadelphia, United States of America
Impact: Pirtobrutinib, a Bruton’s Tyrosine Kinase (BTK) inhibitor, triggers measurable reductions in lactate, alanine, and choline that function as noninvasive imaging biomarkers of response. Metabolic imaging enables early treatment response detection, supporting precision monitoring and management of mantle cell lymphoma (MCL).
  Figure 367-02-013.  MRI Assessment of Cancer Therapies in Immunocompetent Tumor Xenografts on the Chicken Embryo Chorioallantoic Membrane
Núria Profitós-Pelejà1, Gema Gorjón-de-Pablo, Miranda Fernández-Serrano, Margarida Julià-Sapé, Ana Candiota, Gaël Roué, Silvia Lope-Piedrafita
Josep Carreras Leukaemia Research Institute, Badalona, Spain
Impact: Coupling the CAM assay with longitudinal MRI analysis offers a promising alternative for studying individual tumor biology and accelerating the development of tailored anticancer therapies.
  Figure 367-02-014.  Mp-fMRI Reveals Enhanced Vascular Remodeling with Combined VEGF Monoclonal Antibody and HIF-2α Inhibitor Treatment
Yuchan Yang, Jiejun Cheng, Mengxiao Liu, Chunyang Xu, Zhigang Gong, Wenli Tan, Le Fu
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
Impact: Combined VEGF-HIF-2α inhibition optimizes ovarian cancer therapy; mp-fMRI enables non-invasive response monitoring.
  Figure 367-02-015.  A Melanin-Based Bimetallic Nanozyme for MRI-Guided Thermo-Chemodynamic Combination Therapy against Glioblastoma
Yuyang Yao, Ying Shi, jianxiu lian, Yue Liu, Pengfei Liu
The First Affiliated Hospital of Harbin Medical University, Harbin, China
Impact: This study presents a theranostic nanoplatform capable of crossing the blood-brain barrier and enabling MRI-guided precision therapy, thereby significantly enhancing glioblastoma treatment efficacy and prolonging survival in glioblastoma

Back to the Program-at-a-Glance

© 2026 International Society for Magnetic Resonance in Medicine